Genmab is an international biotechnology company that develops novel antibody-based medicines and product candidates for cancer and other serious diseases, generating revenue through both direct product sales and royalties from partnered medicines. The company commercializes approved therapies including EPKINLY/TEPKINLY (a bispecific antibody for B-cell malignancies) and Tivdak (an antibody-drug conjugate for cervical cancer), while also receiving royalties and milestone payments from six approved partner medicines developed using Genmab technology, such as Johnson & Johnson's DARZALEX and RYBREVANT. The business model combines revenue from Genmab-owned commercialization efforts in key markets with a royalty stream from collaborative partners, while advancing a pipeline of late-stage programs and leveraging proprietary antibody technology platforms (DuoBody, HexaBody, and ADC platforms) to develop next-generation therapeutics.